Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 525,384
  • Shares Outstanding, K 70,902
  • Annual Sales, $ 430 K
  • Annual Income, $ -88,450 K
  • 60-Month Beta 0.11
  • Price/Sales 1,188.36
  • Price/Cash Flow N/A
  • Price/Book 2.63
Trade ALT with:

Options Overview Details

View History
  • Implied Volatility 108.72% ( -88.13%)
  • Historical Volatility 92.98%
  • IV Percentile 26%
  • IV Rank 14.43%
  • IV High 356.79% on 10/24/23
  • IV Low 66.90% on 08/23/23
  • Put/Call Vol Ratio 0.27
  • Today's Volume 6,821
  • Volume Avg (30-Day) 8,025
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 92,072
  • Open Int (30-Day) 104,435

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.37
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.64 +14.10%
on 06/18/24
8.49 -24.20%
on 06/24/24
-0.89 (-12.21%)
since 05/24/24
3-Month
5.64 +14.10%
on 06/18/24
11.01 -41.55%
on 04/01/24
-2.21 (-25.61%)
since 03/26/24
52-Week
2.09 +207.89%
on 10/23/23
14.84 -56.64%
on 02/28/24
+2.98 (+86.52%)
since 06/26/23

Most Recent Stories

More News
Altimmune (ALT) Stock Soars 27%: Phase 2 Data on Obesity Drug Ignites Market Optimism

In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...

ALT : 6.46 (-12.82%)
Altimmune (ALT) Stock Soars 27%: Phase 2 Data on Obesity Drug Ignites Market Optimism

In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...

ALT : 6.46 (-12.82%)
Stocks Set to Open Mixed as Investors Await Key U.S. Inflation Data and Fed Speak

September S&P 500 E-Mini futures (ESU24) are up +0.04%, and September Nasdaq 100 E-Mini futures (NQU24) are down -0.11% this morning as market participants looked ahead to comments from Federal Reserve...

ESU24 : 5,533.00 (-0.07%)
NQU24 : 19,972.75 (unch)
PLTR : 24.05 (-2.08%)
AVGO : 1,583.32 (+0.16%)
NVDA : 123.66 (-1.93%)
SWBI : 14.74 (-0.14%)
FDS : 417.34 (-0.44%)
NKE : 94.24 (-0.54%)
FDX : 295.01 (+15.07%)
MU : 141.65 (+0.38%)
WBA : 15.66 (-0.25%)
GIS : 64.43 (-4.21%)
Invest in the GLP-1 Drug Market With This New ETF

The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...

ZLDPF : 126.5200 (+0.40%)
LLY : 900.17 (-0.49%)
NVO : 143.89 (-2.06%)
OZEM : 26.48 (-1.82%)
ALT : 6.46 (-12.82%)
3 Monster Stocks in the Making You Can Buy Right Now

These stocks might not be small for too much longer.

GS : 454.98 (-0.52%)
LLY : 900.17 (-0.49%)
ALT : 6.46 (-12.82%)
AXSM : 78.13 (-1.11%)
VKTX : 47.18 (-1.30%)
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

LLY : 900.17 (-0.49%)
ALT : 6.46 (-12.82%)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

VKTX : 47.18 (-1.30%)
LLY : 900.17 (-0.49%)
PFE : 27.44 (-1.96%)
ALT : 6.46 (-12.82%)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Viking Therapeutics just might be an attractive acquisition target for Pfizer.

LLY : 900.17 (-0.49%)
NVO : 143.89 (-2.06%)
ALT : 6.46 (-12.82%)
PFE : 27.44 (-1.96%)
VKTX : 47.18 (-1.30%)
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?

Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.

UBS : 29.27 (-1.78%)
VKTX : 47.18 (-1.30%)
NVO : 143.89 (-2.06%)
LLY : 900.17 (-0.49%)
ALT : 6.46 (-12.82%)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

VKTX : 47.18 (-1.30%)
AMGN : 313.37 (-1.86%)
LLY : 900.17 (-0.49%)
ENDP : 0.2926 (-5.00%)
PFE : 27.44 (-1.96%)
ALT : 6.46 (-12.82%)

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 8.68
2nd Resistance Point 8.10
1st Resistance Point 7.76
Last Price 6.49
1st Support Level 6.84
2nd Support Level 6.26
3rd Support Level 5.92

See More

52-Week High 14.84
Fibonacci 61.8% 9.97
Fibonacci 50% 8.47
Fibonacci 38.2% 6.96
Last Price 6.49
52-Week Low 2.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar